Clinical trial · Observational
IFACT: Incidental Findings in Advanced Cancer Therapy
NCT02217891CI-TRIAL-00063879IFACTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Semi-structured interview | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- participants from existing MSK protocol 12-245
- description
- Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings. Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling.
- interventionNames
- Behavioral: Semi-structured interview
Primary outcomes (1)
- measure
- qualitive data
- timeFrame
- one time
- description
- The study team will review and code the interview transcripts through a process of independent and collaborative thematic content analysis,(25-28) using ATLAS.ti (a qualitative data analysis software package) to facilitate the analysis process (29).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Part 1: * Patient enrolled on MSK protocol #12-245 * Living patient age 18 or older * Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer * Patient residing in New York metro-area Part 2: * Living patient age 18 or older * Consented to Part C of IRB#12-245 and has received results regardless if thereir was a pathogenic variant * Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer * Patient residing in New York metro-area Exclusion Criteria for Part 1 and 2: * Non-English speakers because we do not have the resources to conduct and translate the interviews into other languages. * Patient unwilling or unable to provide informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.